NNP-1 inhibitors belong to a class of compounds that function by targeting and modulating the activity of the NNP-1 protein, a key enzyme involved in biochemical processes such as signal transduction, metabolic regulation, or protein-protein interactions. These inhibitors are generally designed to interfere with the active site of the NNP-1 enzyme, often binding through competitive or non-competitive inhibition mechanisms. The specificity and affinity of NNP-1 inhibitors depend heavily on the structural characteristics of both the inhibitor and the enzyme. Researchers in chemical biology have focused extensively on the development of synthetic NNP-1 inhibitors, employing techniques such as high-throughput screening, rational drug design, and molecular docking to identify molecules with precise binding capabilities. The inhibition mechanism can also vary, with some inhibitors mimicking the natural substrates of NNP-1, while others may bind to allosteric sites, leading to conformational changes in the enzyme's structure, thus affecting its catalytic function.
The design and study of NNP-1 inhibitors involve detailed characterization through various techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry, which help determine the three-dimensional arrangement of atoms within the enzyme-inhibitor complex. Structure-activity relationship (SAR) studies are crucial in optimizing these inhibitors, allowing researchers to tweak molecular features like hydrophobicity, hydrogen bonding, and steric hindrance to improve binding efficiency and selectivity. NNP-1 inhibitors are of great interest in fields focused on elucidating complex enzymatic pathways, with researchers using these molecules as chemical tools to probe and dissect the function of NNP-1 in various cellular contexts. Advances in computational modeling and bioinformatics also assist in the iterative design process, enabling predictive models that guide the synthesis of novel inhibitor scaffolds and analogs for further exploration of their biochemical properties.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D intercalates into DNA, which could downregulate NNP-1 by obstructing the transcription initiation complex and preventing RNA polymerase from effectively transcribing the gene. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
As a potent inhibitor of RNA polymerase II, α-Amanitin could fatally decrease the transcription of NNP-1, reducing the synthesis of its mRNA and subsequent protein levels. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide may downregulate NNP-1 by suppressing transcription factor activity, leading to a decrease in the initiation and elongation phases of NNP-1 mRNA synthesis. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB could inhibit transcriptional elongation by RNA polymerase II, leading to a decrease in NNP-1 mRNA levels by preventing the transition from transcription initiation to elongation. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Cordycepin could prematurely terminate the elongation of NNP-1 mRNA during transcription, resulting in the reduction of full-length NNP-1 transcripts and a decrease in protein production. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
By inhibiting cyclin-dependent kinases, Flavopiridol could downregulate NNP-1 expression via the suppression of cell cycle progression-related transcription factors that are critical for NNP-1 gene expression. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Rocaglamide could inhibit the initiation phase of protein translation, which would lead to a reduction in NNP-1 protein synthesis, indirectly diminishing the functional outcomes of NNP-1 activity. | ||||||
Leptomycin B | 87081-35-4 | sc-358688 sc-358688A sc-358688B | 50 µg 500 µg 2.5 mg | $107.00 $416.00 $1248.00 | 35 | |
By inhibiting the export of mRNA, Leptomycin B could indirectly decrease the amount of NNP-1 mRNA available in the cytoplasm for translation, leading to lower levels of NNP-1 protein. | ||||||
Ellipticine | 519-23-3 | sc-200878 sc-200878A | 10 mg 50 mg | $145.00 $569.00 | 4 | |
By intercalating within the DNA structure, Ellipticine could hinder the transcription machinery, leading to a reduced transcription rate of the NNP-1 gene and lower mRNA availability. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
Mitoxantrone, through its intercalation into DNA and inhibition of topoisomerase II, could result in decreased transcriptional activity of NNP-1 by disrupting essential DNA replication and transcription processes. | ||||||